Company News

2023-10-04
ImmuneOnco is about to report phase II clinical data of Timdarpacept (IMM01) at the 2023 American Society of Hematology (ASH) Annual Meeting
On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.
View more
2023-09-27
ImmuneOnco: IMM47, an anti-CD24 humanized antibody, successfully completed its first patient dosing in the Australian Phase I clinical trial
On September 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the newly developed humanized IgG1 CD24 antibody, IMM47, successfully completed the first subject enrollment and dosing in the Australian phase I clinical trial. This is another milestone achievement in the company's rapid development.
View more
2023-09-26
The top medical Journal ‘Frontiers in Oncology’ published the preclinical study results of ImmuneOnco’s drug candidate IMM40H
On September 26, 2023,the R&D team of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported the preclinical research results of IMM40H under the tittle of ‘The Novel High-Affinity Humanized Antibody IMM40H Targets CD70, Eliminates Tumors Via Fc-mediated Effector Functions, and Interrupts CD70/CD27 Signaling’in the top journal Frontiers in Oncology’
View more
2023-09-13
ImmuneOnco published the preclinical research results of IMM47 in the journal "Antibody Therapeutics"
Recently, the R&D team of ImmuneOnco (Hong Kong Stock Exchange stock code: 01541.HK) reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".
View more
2023-09-11
ImmuneOnco completed IMM27M Phase I dose escalation and determined recommended Phase II dose
On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM27M, an independently developed ADCC-enhanced CTLA-4 antibody, completed the phase I dose escalation patient enrollment and determined the recommended phase II dose.
View more
2023-09-11
IMM2510 of ImmuneOnco completed Phase I dose escalation and determined recommended phase II dose
On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM2510, a PD-L1/vEGF bispecific fusion protein independently developed by ImmuneOnco, completed Phase I dose escalation and determined the recommended Phase II dose.
View more
Total 57 12345678910
0.086144s